AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENTIncentive Compensation Agreement • March 22nd, 2019 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Amended and Restated Incentive Compensation Agreement, dated as of March 21, 2019, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Elizabeth L. Williams (the “Executive”), and replaces and supersedes in its entirety the Incentive Compensation Agreement, dated as of March 6, 2017, between the Company and the Executive.
